Injective Labs

Injective is the first fully decentralized smart contracts platform optimized for building decentralized finance applications such as exchanges, derivatives, prediction markets, and options. 

Injective aims to solve critical scalability and user experience bottlenecks that trouble decentralized exchanges (DEXs).

Injective was founded in 2018 by Eric Chen and Albert Chon. The company is headquartered in New York, New York.


Injective provides solutions tailored for DeFi developers to quickly build and launch dApps for widespread use. Injective uniquely provides traditional finance infrastructures, such as an order book module, on-chain and is highly interoperable with prominent layer 1s, including Ethereum, Evmos, Axelar, and Moonbeam.


Injective is based on the Cosmos-SDK and Ethereum network that integrates a verifiable delay function (VDF) to prevent trade manipulation and front-running. It was selected as one of the eight projects to join the Binance Labs Incubation Program in 2018.


Injective has already processed over 90 million transactions, surpassing popular blockchains such as Solana despite only being live for a few months. dApps built on Injective generated over $7 billion in cumulative volume, becoming one of the fastest growing ecosystems in the industry today.


Injective is backed by Pantera Capital, Jump Crypto, Binance, Hashed, BH Digital, Cadenza Ventures, CMS, QCP Capital, Mark Cuban, BlockTower, and others. The company raised $40M in new round on Aug 10, 2022. This brings Injective's total funding to $56.7M to date.



  • Year founded: 2018
  • Funding Info: $56.7M over 4 Rounds (Latest Funding Type: Venture- Series Unknown)
  • Yearly Revenue: NA
  • Employee Size: 11-50
  • Business Valuation: NA
  • City/Town: New York
  • State: New York
  • Country: United States
Related businesses